OKYO Pharma Announces Chairman and Founder Acquires Shares OKYO Pharma (NASDAQ: OKYO) announced that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, purchased 10,119 ordinary shares on NASDAQ at $1.59 on March 19, 2026, bringing his total holdings to 10,526,416 shares.The transaction is an insider purchase and updates the chairman's aggregate beneficial ownership.

#OKYO OKYO Pharma Announces Chairman and Founder Acquires Shares

www.stocktitan.net/news/OKYO/okyo-pharma-an...

OKYO Pharma Announces Director Acquires Shares OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed

#OKYO OKYO Pharma Announces Director Acquires Shares

www.stocktitan.net/news/OKYO/okyo-pharma-an...

Biotech executive buys more OKYO stock, lifting stake to 108,920 shares Chief Development Officer Gary Jacob bought the shares on Nasdaq at $1.59 each, lifting his holding to 108,920 as OKYO develops therapies for eye pain.

#OKYO OKYO Pharma Announces Chief Development Officer and Director Acquires Shares

www.stocktitan.net/news/OKYO/okyo-pharma-an...

OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain OKYO Pharma (Nasdaq: OKYO) reported exploratory Phase 2a patient-reported quality-of-life (QoL) improvements with 0.05% urcosimod for neuropathic corneal pain (NCP). Treatment (n=6) showed greater mean improvements versus placebo (n=6) in emotional well-being, mood, and time spent thinking about eye pain.Findings will be presented at ARVO 2026 and the company plans larger confirmatory Phase 2b/3 studies to validate these results.

#OKYO OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain

www.stocktitan.net/news/OKYO/okyo-pharma-re...

今回も選りすぐりの演者さんが一同に出演👏

『メガマニナイトVol8』
🗺️渋谷gee-ge.
🗓️2026/4/21(火)
🚪18:15
🎶18:45
🎫¥3,300+1D(¥700)

出演:OKYO 北原ゆか 青空 uiuni 真理

入場:チケット 各アーティストの取置 TIGET予約

tiget.net/events/470600

#OKYO
#北原ゆか
#青空
#uiuni
#真理
#渋谷gee-ge.

#メガマニナイト

Le chef de la potatopolice #Hasegawa les dirige via un collier permettant de communiquer mais aussi qui peut exploser si la mission n'est pas finalisée à temps.
La jeune recrue #Okyo les aide pendant leurs enquêtes. Ils ont aussi des armes et des véhicules à leur disposition.

Le chef de la cyberpolice #Hasegawa les dirige via un collier permettant de communiquer mais aussi qui peut exploser si la mission n'est pas finalisée à temps.
La jeune recrue #Okyo les aide pendant leurs enquêtes. Ils ont aussi des armes et des véhicules à leur disposition.

La #ilustradora y redactora #KaoruYamada #山田カオル residente en #Okyo, nació en #Kamakura, #Japón. Yamada encuentra la #belleza en la naturaleza, en las expresiones y gestos de las personas, y en los seres vivos. #museoparticular #painting #art

La ilustradora y redactora Kaoru Yamada (山田カオル), residente en Okyo, nació en Kamakura, Japón. Yamada encuentra la belleza en la naturaleza, en las expresiones y gestos de las personas, y en los seres vivos. Cree que las personas encuentran la belleza cuando están en paz y tienen el espacio para sentir compasión. - “Como ilustradora, disfruto dibujando paisajes estacionales e ilustraciones de la vida cotidiana.

La #ilustradora y redactora #KaoruYamada #山田カオル residente en #Okyo, nació en #Kamakura, #Japón. Yamada encuentra la #belleza en la naturaleza, en las expresiones y gestos de las personas, y en los seres vivos. #museoparticular #painting #art
⬇️⬇️⬇️

FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain OKYO Pharma (Nasdaq: OKYO) announced the FDA authorized a single-patient expanded access Investigational New Drug (IND 176297) application for urcosimod 0.05% to treat a patient with severe neuropathic corneal pain (NCP).The company said it will provide urcosimod under the physician-sponsored compassionate use IND and noted urcosimod previously received FDA fast track designation. OKYO expects to initiate a 120-patient Phase 2b/3 multiple-dose study of urcosimod for NCP in 2026.

#OKYO FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain

www.stocktitan.net/news/OKYO/fda-approves-c...

Trade Alerts, Monday January 12, 2026 – Crystal Equity Research

Small-cap stocks with improving money flow, Mon Jan 12th - #OKYO #HGBL #WLFC #SIFY #PLTS #MBRX #LYRA #IVA #EVTV #CPSH #BRNS #ADTN #EEX #CLW - More: crystalequityresearch.com/trade-alerts... - #smallcap

OKYO Pharma Announces Chairman and Founder Acquires Shares OKYO Pharma (NASDAQ: OKYO) announced on Dec 15, 2025 that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 24,551 ordinary shares on NASDAQ.After the purchase, the Chairman's total holding increased to 10,516,297 shares. OKYO is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition currently without an FDA-approved therapy.

#OKYO OKYO Pharma Announces Chairman and Founder Acquires Shares

www.stocktitan.net/news/OKYO/okyo-pharma-an...

#OKYO OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain

www.stocktitan.net/news/OKYO/okyo-pharma-an...

OKYO Pharma Announces Chairman and Founder Acquires Shares OKYO Pharma (NASDAQ: OKYO) announced that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 27,051 ordinary shares on NASDAQ on Dec 3, 2025.The purchase increases the Chairman's total holding to 10,491,746 shares. The company is developing urcosimod for neuropathic corneal pain, a condition with no FDA-approved therapy.

#OKYO OKYO Pharma Announces Chairman and Founder Acquires Shares

www.stocktitan.net/news/OKYO/okyo-pharma-an...

OKYO Pharma Announces Chairman and Founder Acquires Shares OKYO Pharma (NASDAQ: OKYO) announced that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 82,018 ordinary shares on NASDAQ on November 21, 2025.The purchase increases the Chairman's total holding to 10,464,695 shares. The company is developing urcosimod for neuropathic corneal pain (NCP), an ocular condition without an FDA-approved therapy.

#OKYO OKYO Pharma Announces Chairman and Founder Acquires Shares

www.stocktitan.net/news/OKYO/okyo-pharma-an...

80% Pain Reduction: OKYO's Urcosimod Breakthrough for Untreatable Corneal Pain in Phase 2 Trial OKYO Pharma advances urcosimod to 100-patient trial following 75% success rate in Phase 2 NCP study. Fast-Track designated drug targets neuropathic corneal pain with 2026 data readout.

#OKYO OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

www.stocktitan.net/news/OKYO/okyo-pharma-an...

OKYO Secures $1.9M to Fast-Track Revolutionary Eye Pain Drug with No Current FDA Treatment Novel urcosimod drug advances toward first-ever FDA approval for neuropathic corneal pain. Non-dilutive funding boosts development timeline. Learn development milestones.

#OKYO OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain

www.stocktitan.net/news/OKYO/okyo-pharma-re...

#OKYO
#OkyoPharma just reported positive Phase 2 results in neuropathic corneal pain, a chronic eye condition with no FDA-approved treatment.
75% of patients saw over 80% pain reduction with urcosimod, showing strong potential in a truly underserved space.
prismmarketview.com/okyo-pharma-...

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain OKYO Pharma (NASDAQ: OKYO) has announced positive Phase 2 clinical trial results for urcosimod in treating neuropathic corneal pain (NCP). The trial demonstrated that 75% of per-protocol patients receiving 0.05% urcosimod achieved over 80% reduction in pain after 12 weeks of treatment.Key findings include a statistically significant reduction in mean pain scores (p-value = 0.025) for the 0.05% urcosimod group, with efficacy observed as early as Week 4. The drug showed particularly strong results in patients with moderate to severe NCP pain scores. Importantly, no serious adverse events were reported among the 18 trial participants.The company plans to meet with the FDA to discuss next steps for urcosimod, which has already received Fast Track designation. OKYO is also planning to arrange an Expanded Access program for the drug, pending FDA approval.

#OKYO OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

www.stocktitan.net/news/OKYO/okyo-pharma-un...

Goldman Research Boosts OKYO Pharma Target 60% as Eye Drug Trial Ends Early: Key Catalyst Ahead Early Phase 2 trial completion signals potential breakthrough in eye disease treatment. Fast Track drug shows promise for billion-dollar market. See full analysis.

#OKYO Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

www.stocktitan.net/news/OKYO/goldman-small-...

JUST IN: ( NASDAQ: #OKYO ) OKYO Pharma to Present at the Bio International Convention

Rainy Tokyo night

A photo of a rainy night in Tokyo from our night photography series:

tokyo.for91days.com/tokyo-at-nig...

#urbangaze #okyo #japan #umbrella #streetphotography #photography

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume declines, Wed May 7th - #WRD #SYTA #OKYO #KAVL #SNCR #MYGN #LFVN #HAIN #GDRX #YAAS #ARIS #BGS #EPC #GFR #MAGN #RVLV #VSTS #ALZN #BNR #CEVA - More: crystalequityresearch.com/SmCpStr/ - #smallcap

FDA Fast-Tracks Novel Eye Pain Drug: OKYO's Urcosimod Targets Untreated Corneal Condition First potential FDA-approved therapy for neuropathic corneal pain receives Fast Track status. Accelerated development could address urgent unmet need. See timeline.

#OKYO FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain

www.stocktitan.net/news/OKYO/fda-grants-oky...

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain OKYO Pharma announces plans to accelerate the development of urcosimod for treating Neuropathic Corneal Pain (NCP). The company is closing its Phase 2 trial early after 17 patients completed the study at Tufts Medical Center in Boston. The trial, initiated in October 2024, was designed as a double-masked, randomized, 12-week placebo-controlled study. The decision to end early stems from OKYO's desire to analyze the current data and expand to a multicenter trial. Several patients who completed the trial have requested continued compassionate use of urcosimod. The company expects data analysis to take approximately 6 weeks and plans to meet with the FDA to discuss accelerated development plans. Urcosimod has already shown favorable safety and placebo-like tolerability in a previous 240-patient Phase 2 trial. NCP currently has no FDA-approved therapy, making this development significant for patients who have had limited success with other treatments.

#OKYO OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

www.stocktitan.net/news/OKYO/okyo-pharma-an...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks in new uptrend with average directional index, Wed Apr 23rd - #AREN #OKYO #GAUZ #VBTX #SIGA #RLMD #PESI #NEON #SNOA #JANX #IRIX #FHTX #EDIT #DRCT #CNCK #AMLX - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Clinical Trial Breakthrough: New Stability Data Strengthens Urcosimod's Path to FDA Approval Key stability milestone achieved for NCP drug candidate with 97.4% preservation rate. Critical FDA requirement met, advancing treatment for billion-dollar market. Full analysis inside.

#OKYO OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

www.stocktitan.net/news/OKYO/okyo-pharma-an...

good morning have a terrific tuesday is written in red letters on a white background . ALT: good morning have a terrific tuesday is written in red letters on a white background .

Is the GaijinSpot #GaijinGuide the best place to post about #Jvloggers? gaijinspot.boards.net/board/8/famo... There are complaints on Youtube comments that JapanLife removal of posts #japanlife #japan #tokyolife #okyo #japanvloggers #youtubers #realjapan

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain OKYO Pharma (NASDAQ: OKYO) has filed an application for Fast Track designation with the FDA for its drug urcosimod (formerly OK-101) to treat neuropathic corneal pain. This condition, affecting tens of thousands globally, is characterized by chronic, severe eye discomfort with no current FDA-approved treatment.The company is developing urcosimod for both neuropathic corneal pain and inflammatory dry eye disease, the latter representing a multi-billion-dollar market opportunity. Fast Track designation is designed to expedite the development and review process for drugs treating serious conditions that lack FDA-approved treatments.

#OKYO OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain

www.stocktitan.net/news/OKYO/okyo-pharma-fi...

Revolutionary Eye Drug Urcosimod Targets Two Major Unmet Medical Needs OKYO's lead drug candidate receives USAN designation as Urcosimod, advancing treatment for dry eye disease and neuropathic corneal pain with promising Phase 2 data.

#OKYO OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

www.stocktitan.net/news/OKYO/okyo-pharma-an...